Alzheimer’s Foundation of America Statement on FDA Approving New Alzheimer’s Medication
(January 6, 2023)—“Today is a day of hope and optimism that we are gaining ground in the fight against Alzheimer’s.
“We are hopeful that the FDA’s accelerated approval of lecanemab will make a positive difference in the lives of individuals and families affected by Alzheimer’s disease. As with any medication, patient access and affordability to all of those in need is of substantial importance.
“This is another step forward, but not the end of the journey. We urge the federal government to further invest in Alzheimer’s research funding and caregiver support services to provide the more than 6 million American families affected by Alzheimer’s disease with additional help today and hope for tomorrow.”
